Amylyx Pharmaceuticals, Inc. AMLX Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amylyx Pharmaceuticals, Inc.'s deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amylyx Pharmaceuticals, Inc.'s deferred tax assets and other non-current assets?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported deferred tax assets and other non-current assets of $2.5M in Q1 2026.
- How has Amylyx Pharmaceuticals, Inc.'s deferred tax assets and other non-current assets changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s deferred tax assets and other non-current assets increased by 22627.3% year-over-year, from $11K to $2.5M.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s deferred tax assets and other non-current assets?
- Over 3 years (2022 to 2025), Amylyx Pharmaceuticals, Inc.'s deferred tax assets and other non-current assets has grown at a 75.0% compound annual growth rate (CAGR), from $466K to $2.5M.